High dose vitamin D has minimal benefit in critically ill patients, finds NEJM study
AURORA, Colo. - Preclinical data suggest that vitamin D is a potent immunomodulatory agent that is essential for lung development and function and may improve clinical outcomes in critical patients.
A new major study has found that high doses of vitamin D do not reduce mortality or improve other non-fatal outcomes for critically ill patients. The study was conducted by the National Heart, Lung and Blood Institute's Prevention and Early Treatment of Acute Lung Injury (PETAL) Network. The results of the Vitamin D to Improve Outcomes by Leveraging Early Treatment (VIOLET) study are published in the online issue of the New England Journal of Medicine.
The researchers conducted a randomized, double-blind, placebo-controlled, phase 3 trial of early vitamin D3 supplementation in critically ill, vitamin D–deficient patients who were at high risk for death.
"The VIOLET study did not show benefit from vitamin D supplementation in this population of critically ill patients," said Ginde. "However, the study gives us a model to intervene in the earliest stage of critical illness, which will yield improved care and better health for our patients in the future."
In this case, the researchers sought to determine whether vitamin D supplementation could reduce morbidity and mortality in critically ill patients. A deficiency of vitamin D is a common risk factor for worse outcomes in critically ill patients. While vitamin D is most known for strong bone formation, it also helps to fight infections, is a potent anti-inflammatory agent, and is essential for lung development and function.
"We wanted to study whether rapidly correcting vitamin D deficiency could improve outcomes for patients with a critical illness," Talmor said. "Previous studies suggested that this treatment might reduce mortality, so we wanted to definitively show whether high doses of vitamin D could reduce all-cause, all-location 90-day mortality in those critically ill patients."
In this study, the NHLBI PETAL Network conducted a controlled study of patients who needed admission into intensive care units. Among those cases, patients had pneumonia, sepsis, shock, respiratory failure, and other critical conditions.
"This is the kind of important question that the PETAL network was designed to answer efficiently," said James Kiley, PhD, director of the Division of Lung Diseases at the NHLBI. "This trial could not have been performed without the successful collaboration between emergency medicine and critical care that the PETAL network facilitated."
From April 2017 through July 2018, 2,624 patients at 44 hospitals consented to participate in the study. Of those, 1,360 screened as vitamin D deficient and ultimately 1,078 were included in the final analysis. About half received vitamin D and half received a placebo, and the vitamin D group achieved rapid correction of vitamin D deficiency in the blood. Patients were followed for 90 days, and researchers found no difference in mortality rates, hospital length of stay, or time on mechanical ventilation between the two groups.
"While we hoped that vitamin D supplementation might prove beneficial to critically ill patients, our large study does not support early testing for or treatment of vitamin D deficiency in those patients," Ginde said.
For further reference log on to:
University of Colorado Anschutz Medical Campus